|DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology|
VT DeVita, TS Lawrence, SA Rosenberg
Lippincott Williams & Wilkins, 2008
|Cancer regression in patients after transfer of genetically engineered lymphocytes|
RA Morgan, ME Dudley, JR Wunderlich, MS Hughes, JC Yang, ...
Science 314 (5796), 126-129, 2006
|Cancer immunotherapy: moving beyond current vaccines|
SA Rosenberg, JC Yang, NP Restifo
Nature medicine 10 (9), 909-915, 2004
|A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone|
SA Rosenberg, MT Lotze, LM Muul, AE Chang, FP Avis, S Leitman, ...
New England Journal of Medicine 316 (15), 889-897, 1987
|Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes|
ME Dudley, JR Wunderlich, PF Robbins, JC Yang, P Hwu, ...
Science 298 (5594), 850-854, 2002
|A randomized trial of bevacizumab, an anti–vascular endothelial growth factor antibody, for metastatic renal cancer|
JC Yang, L Haworth, RM Sherry, P Hwu, DJ Schwartzentruber, ...
New England Journal of Medicine 349 (5), 427-434, 2003
|Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer|
SA Rosenberg, MT Lotze, LM Muul, S Leitman, AE Chang, ...
New England journal of medicine 313 (23), 1485-1492, 1985
|Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma|
SA Rosenberg, BS Packard, PM Aebersold, D Solomon, SL Topalian, ...
New England Journal of Medicine 319 (25), 1676-1680, 1988
|T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial|
DW Lee, JN Kochenderfer, M Stetler-Stevenson, YK Cui, C Delbrook, ...
The Lancet 385 (9967), 517-528, 2015
|Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2|
RA Morgan, JC Yang, M Kitano, ME Dudley, CM Laurencot, ...
Molecular therapy 18 (4), 843-851, 2010
|A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes|
SA Rosenberg, P Spiess, R Lafreniere
Science 233 (4770), 1318-1321, 1986
|Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapycomplete regressions in melanoma|
SA Rosenberg, JC Yang, RM Sherry, US Kammula, MS Hughes, ...
Clinical cancer research 17 (13), 4550-4557, 2011
|High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993|
MB Atkins, MT Lotze, JP Dutcher, RI Fisher, G Weiss, K Margolin, ...
Journal of clinical oncology 17 (7), 2105-2105, 1999
|Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma|
SA Rosenberg, JC Yang, DJ Schwartzentruber, P Hwu, FM Marincola, ...
Nature medicine 4 (3), 321-327, 1998
|Adoptive cell transfer as personalized immunotherapy for human cancer|
SA Rosenberg, NP Restifo
Science 348 (6230), 62-68, 2015
|Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer|
E Tran, S Turcotte, A Gros, PF Robbins, YC Lu, ME Dudley, ...
Science 344 (6184), 641-645, 2014
|T lymphocyte-directed gene therapy for ADA− SCID: initial trial results after 4 years|
RM Blaese, KW Culver, AD Miller, CS Carter, T Fleisher, M Clerici, ...
Science 270 (5235), 475-480, 1995
|Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma|
ME Dudley, JR Wunderlich, JC Yang, RM Sherry, SL Topalian, NP Restifo, ...
Journal of clinical oncology: official journal of the American Society of …, 2005
|Adoptive cell transfer: a clinical path to effective cancer immunotherapy|
SA Rosenberg, NP Restifo, JC Yang, RA Morgan, ME Dudley
Nature Reviews Cancer 8 (4), 299-308, 2008
|Adoptive immunotherapy for cancer: harnessing the T cell response|
NP Restifo, ME Dudley, SA Rosenberg
Nature Reviews Immunology 12 (4), 269-281, 2012